Effectiveness of tocilizumab in a COVID-19 patient with cytokine release syndrome

Basit Öğe Kaydı
dc.contributor.authorUslu, Sadettin
dc.date.accessioned2024-11-07T10:40:10Z
dc.date.available2024-11-07T10:40:10Z
dc.date.issued2020
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractCytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by many factors such as infections. CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis. Tocilizumab (TCZ), an interleukin-6 (IL-6) inhibitor, may ameliorate the CRS associated with severe COVID-19 and thus improve clinical outcomes. We present a case of life-threatening CRS caused by COVID-19 infection successfully treated with TCZ. © EFIM 2020
dc.identifier.doi10.12890/2020_001731
dc.identifier.issn2284-2594
dc.identifier.issue6
dc.identifier.scopus2-s2.0-85117084548
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.12890/2020_001731
dc.identifier.urihttps://hdl.handle.net/11480/11479
dc.identifier.volume7
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherSMC Media Srl
dc.relation.ispartofEuropean Journal of Case Reports in Internal Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectCOVID-19
dc.subjectCytokine release syndrome
dc.subjectTocilizumab
dc.titleEffectiveness of tocilizumab in a COVID-19 patient with cytokine release syndrome
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu